Statement of Deviation & Variation for the quarter ended 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Novelix Pharmaceuticals filed its Q4 FY2026 (Jan–Mar 2026) fund utilisation statement under SEBI Regulation 32. The company raised three separate capital tranches during the quarter: Rs. 60 lakh (19 Jan 2026), Rs. 1,392 lakh (12 Feb 2026), and Rs. 172.50 lakh (30 Mar 2026) — all via public issue/preferential offers. For the Rs. 1,392 lakh raise, the detailed allocation shows Lab Scale Tech Transfer (Rs. 30L), Lab Interior (Rs. 275L), Lab Equipment (Rs. 350L), Bio Reactors (Rs. 180L), Consumables (Rs. 67L), Travelling & Accommodation (Rs. 54L), Pre-Operative Expenses (Rs. 44L), Working Capital (Rs. 250L allocated, Rs. 300L budgeted), and General Corporate Expenses (Rs. 142L utilised vs Rs. 200L budgeted). The company declared there is no deviation or variation in the utilisation of funds for any of the three raises. Both the Audit Committee and auditors recorded no comments.
No deviations reported. Funds are being deployed as stated in the offer documents, which is a neutral-to-positive signal — it suggests proper governance and adherence to stated capital deployment plans.